FibroBiologics to Present at 9th Annual BFC Global Healthcare Business Development and Investment Conference

Rhea-AI Summary

FibroBiologics (Nasdaq: FBLG) announced that Founder and CEO Pete O’Heeron will present at the 9th Annual BFC Global Healthcare Business Development and Investment Conference on January 11, 2026 in San Francisco.

The company presentation is scheduled for 4:30 p.m. PT on Sunday, January 11, 2026 at The St. Regis. Interested parties may visit the company website or contact info@fibrobiologics.com for more information.

News Market Reaction – FBLG

+6.78% 1.5x vol

55 alerts

+6.78% Session close to close

+40.9% Peak in 27 hr 9 min

$24.28M Market Cap

1.5x Rel. Volume

In the Jan 6 session, FBLG gained 6.78%, reflecting a notable positive market reaction. Argus tracked a peak move of +40.9% during that session. Our momentum scanner triggered 55 alerts that day, indicating high trading interest and price volatility. Trading volume was above average at 1.5x the daily average, suggesting increased trading activity.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +6.8% in the session following this news. A strong positive reaction aligns with Fib...

Analysis

The stock moved +6.8% in the session following this news. A strong positive reaction aligns with FibroBiologics’ pattern of responding to pipeline and platform visibility, such as the patent news that saw a 12.82% move. However, recent capital raises and Nasdaq listing risks in 2025 filings highlight ongoing financing and dilution overhangs that could cap follow-through. Investors watching a surge around this conference appearance would need to weigh prior negative reactions to financings against positive responses to scientific and strategic milestones.

Key Figures

Patent portfolio: 270+ patents issued and pending Conference date: January 11, 2026 Presentation time: 4:30 p.m. PT

3 metrics

Patent portfolio 270+ patents issued and pending Fibroblast-focused therapeutics and potential cures for chronic diseases

Conference date January 11, 2026 9th Annual BFC Global Healthcare BD and Investment Conference

Presentation time 4:30 p.m. PT Company presentation slot at conference

Historical Context

5 past events · Latest: Dec 31 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Dec 31	IND filing	Positive	-7.0%	Filed FDA IND to start Phase 1/2 trials of CYPS317 in psoriasis.
Dec 16	Equity offering	Negative	-8.4%	Closed $1.7M registered direct and concurrent warrant private placement.
Dec 15	Equity offering	Negative	-33.1%	Announced $1.7M registered direct offering with additional warrant proceeds potential.
Dec 10	Patent filing	Positive	+12.8%	Filed U.S. patent for fibroblast-derived chondrocyte spheroid orthopedic platform.
Nov 26	Debt payoff	Positive	+1.5%	Paid off Yorkville convertible notes while keeping SEPA capacity through 2026.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent offerings and balance sheet actions generally aligned with price moves, while the recent IND filing for CYPS317 saw a negative divergence.

Recent Company History

Over the last few months, FibroBiologics reported multiple financing transactions and pipeline steps. November 2025 offerings and warrant structures, plus gold-backed consideration, funded operations but came with dilution and Nasdaq listing-risk disclosures. On Nov 26, 2025, the company paid off SEPA-related debt while keeping capacity for up to $10 million in future stock sales. A December patent filing expanded its fibroblast-based orthopedic platform, and on Dec 31, 2025 FibroBiologics filed an IND to advance CYPS317 in psoriasis. Today’s conference appearance fits into this ongoing capital markets and clinical development narrative.

Key Terms

fibroblasts, fibroblast-derived materials

2 terms

fibroblasts medical

"using fibroblasts and fibroblast-derived materials, today announced that Founder"

Fibroblasts are common cells in connective tissue that manufacture the structural proteins and fibers—like collagen—that form and repair the body's scaffolding, helping wounds heal and tissues hold their shape. For investors, fibroblasts matter because they are frequent targets or tools in drug development, regenerative medicine and safety testing: changes in their behavior can signal whether a therapy will work, cause side effects or enable new medical products, much like a construction crew determines the strength and finish of a building.

fibroblast-derived materials medical

"therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials"

Materials produced or conditioned by fibroblasts—common connective‑tissue cells that secrete the structural proteins and other components tissues use as a scaffold. Investors should care because these biologically sourced materials are used in wound care, tissue engineering, cosmetic and regenerative products; their quality, scalability and regulatory path affect a product’s performance, manufacturing cost and commercial potential, much like the quality of bricks and mortar determines a building’s durability.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HOUSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O’Heeron, will present at the 9^th Annual BFC Global Healthcare Business Development and Investment Conference taking place January 11, 2026, at The St. Regis in San Francisco, California.

FibroBiologics will deliver a company presentation at 4:30 p.m. PT on Sunday, January 11.

For more information, please visit FibroBiologics' website or email FibroBiologics at: info@fibrobiologics.com.

About FibroBiologics

Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.

General Inquiries:
info@fibrobiologics.com

Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com

Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com

FAQ

When will FibroBiologics (FBLG) present at the BFC Global Healthcare conference?

FibroBiologics will present on January 11, 2026 at 4:30 p.m. PT.

Who is presenting for FibroBiologics (FBLG) at the January 11, 2026 conference?

Pete O’Heeron, Founder and CEO, will deliver the company presentation.

Where is the 9th Annual BFC Global Healthcare conference taking place for FibroBiologics (FBLG)?

The conference is at The St. Regis in San Francisco, California.

How can investors access more information about FibroBiologics (FBLG) presentation on January 11, 2026?

Visit the company website or email info@fibrobiologics.com for presentation details.

Will FibroBiologics (FBLG) discuss clinical programs during the January 11, 2026 presentation?

The announcement notes the company is clinical-stage; specific presentation topics were not detailed in the notice.